Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 6/20 | 0.46 |
| ▸ | THRB | P10828 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557062 | 0.91 | THRA (0.50) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL4557812 | 0.86 | THRA (0.47) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL1961045 | 0.81 | MAOB (0.49) | ALDH1A1 | |
| SCHEMBL4556801 | 0.81 | TSHR (0.51) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL4556778 | 0.79 | THRA (0.49) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL4549097 | 0.78 | MAOB (0.43) | — | |
| SCHEMBL7514252 | 0.78 | THRA (0.62) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL4556782 | 0.78 | CYSLTR2 (0.51) | THRATHRBCYSLTR2CYSLTR1PPARD | |
| SCHEMBL4556549 | 0.76 | THRA (0.52) | MEN1ALDH1A1KMT2ATHRATHRB | |
| SCHEMBL3682775 | 0.76 | NR5A1 (0.53) | MEN1ALDH1A1KMT2ATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507549-B2 | Methods for synthesizing glycinols, glyceollins I and II and isoflavenes and chromanes using a Wittig reaction, and compositions made therewith | THE UNIVERSITY OF TOLEDO (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | THE UNIVERSITY OF TOLEDO | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | UGGT1, GCG, UGT8 | MEN1 377/4885ALDH1A1 3179/4885KMT2A 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.